<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01856699</url>
  </required_header>
  <id_info>
    <org_study_id>SuSPect-CAA</org_study_id>
    <nct_id>NCT01856699</nct_id>
  </id_info>
  <brief_title>Superficial Siderosis in Patients With Suspected Cerebral Amyloid Angiopathy</brief_title>
  <acronym>SuSPect-CAA</acronym>
  <official_title>Observational Study on the Prognostic Relevance of Supratentorial Superficial Siderosis in Patients With Suspected Cerebral Amyloid Angiopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of the SuSPect-CAA study is to prospectively evaluate the prognostic significance of&#xD;
      cortical superficial siderosis in patients with suspected cerebral amyloid angiopathy with a&#xD;
      primary focus on future stroke and mortality.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non-traumatic cortical superficial siderosis (cSS) is a common finding in patients with&#xD;
      cerebral amyloid angiopathy (CAA) and can be its sole imaging sign. The clinical features and&#xD;
      course as well as the prognostic significance of cSS in CAA patients remain unclear. In a&#xD;
      retrospective study we have previously shown that cSS might be an important predictor or&#xD;
      warning sign for future intracranial hemorrhage. However, prospective data are missing.&#xD;
&#xD;
      The Superficial Siderosis in Patients with suspected Cerebral Amyloid Angiopathy&#xD;
      (SuSPect-CAA) study is designed as a prospective observational multi-centre cohort study.&#xD;
      Primary objective of the study is to evaluate if cSS is a predictor for future stroke and&#xD;
      mortality (primary endpoint: combined rate of stroke and death after 36 months). Secondary&#xD;
      objectives of the study include 1) to evaluate if cSS represents a marker of future&#xD;
      intracranial haemorrhage, especially at the site of initial siderosis, 2) to describe the&#xD;
      clinical presentation and course of cSS, 3) to assess to associated imaging findings, 4) to&#xD;
      determine the differential diagnoses of cSS.&#xD;
&#xD;
      All subjects presenting to the respective neurological centers (out- or inpatient treatment&#xD;
      with neuroimaging) will be screened. The study population will consist of two patient groups:&#xD;
      1) Patients meeting the modified Boston criteria for probable or possible CAA, i. e. patients&#xD;
      with SS +/- lobar intracerebral hemorrhage or microbleeds in cortico-subcortical localization&#xD;
      and absence of other cause of hemorrhage than CAA will be assigned to the study group. 2)&#xD;
      Patients meeting the classic Boston criteria for possible or probable CAA but without any SS&#xD;
      will be assigned to the control group. A total of 100 patients per group will be enrolled.&#xD;
      Baseline and follow-up assessment at 6, 12, 24, and 36 months will be performed by visits in&#xD;
      the respective neurological outpatient clinic including a structured interview and&#xD;
      neurological exam, neuropsychological tests, EEG and MRI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Combined rate of stroke and death</measure>
    <time_frame>36 months</time_frame>
    <description>All cause mortality and stroke (WHO-definition)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of intracranial hemorrhage</measure>
    <time_frame>6, 12, 24, 36 months</time_frame>
    <description>Rate of any intracranial hemorrhage as assessed by cerebral imaging</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Clinical presentation and course of superficial siderosis</measure>
    <time_frame>0, 6, 12, 24, 36 months</time_frame>
    <description>A detailed analysis on the clinical presentation and course of superficial siderosis will be performed (detailed questionnaire, comprehensive neurological examinations, disability scales, neuropsychological tests)</description>
  </other_outcome>
  <other_outcome>
    <measure>Imaging findings associated with superficial siderosis</measure>
    <time_frame>0, 6, 12, 24, 36 months</time_frame>
    <description>Localization, extent and progression of superficial siderosis will be assessed on MR-imaging. In addition, the prevalence, incidence, localization, number or extent of cerebral microbleeds, white matter disease, and acute ischemic lesions will be determined using follow-up MRI.</description>
  </other_outcome>
  <other_outcome>
    <measure>Differential causes of superficial siderosis</measure>
    <time_frame>0, 6, 12, 24, 36 months</time_frame>
    <description>At the time of patient screening and follow-up we will systematically evaluate the underlying causes of superficial siderosis and potential differential diagnoses based on the available clinical, laboratory and imaging data, as well as published diagnostic criteria.</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">302</enrollment>
  <condition>Intracerebral Hemorrhage</condition>
  <condition>Cerebral Amyloid Angiopathy</condition>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Study Group</arm_group_label>
    <description>Patients with cortical superficial siderosis and possible or probable cerebral amyloid angiopathy meeting the modified Boston criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <description>Patients with possible or probable cerebral amyloid angiopathy meeting the classic Boston criteria but without any cortical superficial siderosis.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood, serum, plasma, CSF&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        hospital based&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria (study group):&#xD;
&#xD;
          -  Fulfillment of the modified Boston criteria for CAA-related hemorrhage with evidence&#xD;
             of supratentorial superficial siderosis on MRI&#xD;
&#xD;
          -  MR-/CT-/digital subtraction (DS) -angiography without evidence of cerebral aneurysm,&#xD;
             arterio-venous malformation (AVM) , AV-fistula or other pathology of relevance (e.g.&#xD;
             tumor, hemorrhagic infarction)&#xD;
&#xD;
          -  A maximum of two lobar or cerebellar intracranial hemorrhages (ICH) (old or acute)&#xD;
&#xD;
          -  Written informed consent by patient or guardian prior to study participation&#xD;
&#xD;
          -  Willingness to participate in follow-up&#xD;
&#xD;
        Inclusion Criteria (control group):&#xD;
&#xD;
          -  Fulfillment of the classic Boston criteria for CAA-related hemorrhage&#xD;
&#xD;
          -  Absence of superficial siderosis on MRI&#xD;
&#xD;
          -  A maximum of two lobar or cerebellar ICHs (old or acute)&#xD;
&#xD;
          -  MR-/CT-/DS -angiography without evidence of cerebral aneurysm, AVM, AV-fistula or&#xD;
             other pathology of relevance (e.g. tumor, hemorrhagic infarction)&#xD;
&#xD;
          -  Written informed consent by patient or guardian prior to study participation&#xD;
&#xD;
          -  Willingness to participate in follow-up&#xD;
&#xD;
        Exclusion Criteria (both groups):&#xD;
&#xD;
          -  Severe medical condition with expected life expectancy &lt;3 years&#xD;
&#xD;
          -  More than two lobar or cerebellar ICH (old or acute)&#xD;
&#xD;
          -  any intracerebral hemorrhage in the deep grey matter (basal ganglia or thalami) or in&#xD;
             the brain stem&#xD;
&#xD;
          -  History of head trauma resulting in loss of consciousness or radiologically visible&#xD;
             traumatic brain injury (contusions, diffuse axonal damage) in the last 5 years prior&#xD;
             to inclusion&#xD;
&#xD;
          -  Cerebral aneurysm or history of aneurysmal subarachnoid hemorrhage&#xD;
&#xD;
          -  Infratentorial siderosis&#xD;
&#xD;
          -  Infratentorial subarachnoid hemorrhage&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Wollenweber, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute for Stroke and Dementia Research, Ludwig-Maximilans-University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jennifer Linn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neuroradiology, Carl Carus University Dresden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christian Opherk, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute for Stroke and Dementia Research, Ludwig-Maximilans-University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Dichgans, MD</last_name>
    <role>Study Director</role>
    <affiliation>Institute for Stroke and Dementia Research, Ludwig-Maximilians-University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ludwig-Maximilians-University</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>May 15, 2013</study_first_submitted>
  <study_first_submitted_qc>May 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2013</study_first_posted>
  <last_update_submitted>August 9, 2017</last_update_submitted>
  <last_update_submitted_qc>August 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ludwig-Maximilians - University of Munich</investigator_affiliation>
    <investigator_full_name>Christian Opherk</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>supratentorial superficial siderosis</keyword>
  <keyword>intracerebral hemorrhage</keyword>
  <keyword>cerebral amyloid angiopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Siderosis</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Hemorrhage</mesh_term>
    <mesh_term>Cerebral Amyloid Angiopathy</mesh_term>
    <mesh_term>Cerebral Amyloid Angiopathy, Familial</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

